Endometrial Cancer Biomarker Changes Following Exposure to Metformin
Status:
Withdrawn
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The investigators will explore the chemopreventive role of metformin. The purpose of this
study is to determine whether, among patients with endometrial cancer, treatment with the
currently approved insulin sensitizing drug metformin increases or decreases pathway
activation distal to the insulin receptor in endometrial cancer tissue. This is a phase IIa
study of metformin to be used to the pre-operative period of women diagnosed with endometrial
cancer by comparing their endometrial biopsy specimens taken at their initial visit and after
4-6 weeks of treatment of metformin on the day of their surgical staging.